Mylan Inks $30M SEC Deal After Not Disclosing EpiPen Probe

By Rachel Graf · September 27, 2019, 11:16 AM EDT

Mylan NV will pay the U.S. Securities and Exchange Commission $30 million to resolve allegations that it failed to warn investors about potential losses tied to an investigation into the drugmaker's...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

SECURITIES AND EXCHANGE COMMISSION v. MYLAN N.V

Case Number

Court

District Of Columbia

Nature of Suit

Securities/Commodities

Date Filed

September 27, 2019

Recent Articles By Rachel

August 19, 2019
UHS Directors Escape Derivative Suit Over Billing Practices
August 15, 2019
SEC Encourages Remediation With Gentle ICO Enforcement
July 23, 2019
3rd Circ. Says Board Observers Not Same As Directors
June 28, 2019
The Biggest Securities Decisions Of 2019: Midyear Report
March 01, 2019
8th Circ. Revives Investor's Suit Over Merger Disclosures
December 14, 2018
Molina Escapes Investor's Suit Over Growth Misstatements
November 13, 2018
High Court Won't Hear $3M Disgorgement Challenge
October 30, 2018
GE Says Power Business Is A Focus Of DOJ, SEC Probes
October 24, 2018
Walgreens Escapes Investor Suit Over Failed Rite Aid Deal
October 05, 2018
High Court Asked To Review $3M Disgorgement Post-Trial Win